Matthew Seibt - Acer Therapeutics Chief Officer
Insider
Matthew Seibt is Chief Officer of Acer Therapeutics
| Age | 52 |
| Phone | 844 902 6100 |
| Web | https://www.acertx.com |
Acer Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6527) % which means that it has lost $0.6527 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7299) %, meaning that it created substantial loss on money invested by shareholders. Acer Therapeutics' management efficiency ratios could be used to measure how well Acer Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Acer Therapeutics currently holds 11.86 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Acer Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Acer Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 47 | |
| James Rolke | Revelation Biosciences | 56 | |
| Alexandra MD | Avenue Therapeutics | 58 | |
| Jonathan MBA | Biomx Inc | 48 | |
| Edward DVM | SAB Biotherapeutics | N/A | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 41 | |
| Assaf Oron | Biomx Inc | 50 | |
| CPA CMA | Lexaria Bioscience Corp | 63 | |
| Inbar GahaliSass | Biomx Inc | N/A | |
| Jane Springer | Hoth Therapeutics | 39 | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Jason Davis | Virax Biolabs Group | 53 | |
| Eddie Sullivan | SAB Biotherapeutics | 59 | |
| Vanessa Carle | Lexaria Bioscience Corp | N/A | |
| Carol Odle | Revelation Biosciences | N/A | |
| Philip Ainslie | Lexaria Bioscience Corp | N/A | |
| Christopher Bunka | Lexaria Bioscience Corp | 62 | |
| Inbal BenjaminiElran | Biomx Inc | N/A | |
| David Jin | Avenue Therapeutics | 34 | |
Management Performance
| Return On Equity | -4.73 | |||
| Return On Asset | -0.65 |
Acer Therapeutics Leadership Team
Elected by the shareholders, the Acer Therapeutics' board of directors comprises two types of representatives: Acer Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acer. The board's role is to monitor Acer Therapeutics' management team and ensure that shareholders' interests are well served. Acer Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acer Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jefferson Davis, Chief Officer | ||
| Jason CPA, VP Controller | ||
| John Klopp, Vice President - Manufacturing | ||
| Donald JD, Chief Sec | ||
| Bernie Paul, Chief Officer | ||
| Harry Palmin, Chief Officer | ||
| Matthew Seibt, Chief Officer | ||
| Tanya Hayden, Chief Officer | ||
| MD FFPM, Chief Officer | ||
| Christopher Schelling, President CEO, Director |
Acer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acer Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.73 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | 52.01 M | |||
| Shares Outstanding | 24.46 M | |||
| Shares Owned By Insiders | 13.78 % | |||
| Shares Owned By Institutions | 29.91 % | |||
| Number Of Shares Shorted | 493.55 K | |||
| Price To Earning | (7.40) X | |||
| Price To Book | 17.26 X | |||
| Price To Sales | 174.52 X |
Pair Trading with Acer Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acer Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acer Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to WW Grainger could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace WW Grainger when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back WW Grainger - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling WW Grainger to buy it.
The correlation of WW Grainger is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as WW Grainger moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if WW Grainger moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for WW Grainger can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Acer Stock
If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |